Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What can oncologists learn from HIV?

Justin Stebbing1, Mark Bower

  • 1Chelsea and Westminster Hospital, London, UK.

The Lancet. Oncology
|July 10, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer-associated fibroblasts as key regulators of lipid metabolism in the tumour microenvironment.

Oncogene·2026
Same author

The Impact of Study Size on COVID-19 Treatment Outcomes: A Meta-Epidemiological Study Comparing Large and Small Randomized Controlled Trials: A Systematic Review and Meta-Analyses.

Reviews in medical virology·2026
Same author

Modelling adipose tissue-cancer crosstalk: a three-dimensional perspective.

Oncogene·2026
Same author

Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer.

Journal for immunotherapy of cancer·2025
Same author

Ten years of oncogene editorship: a decade of transformation.

Oncogene·2025
Same author

Beyond GLP-1s: The blueprint for systemic therapeutics that will reshape aging and medicine.

British journal of clinical pharmacology·2025
Same journal

New report sheds light on cancer disparities in the USA.

The Lancet. Oncology·2026
Same journal

Review highlights gaps in South Africa's cancer care.

The Lancet. Oncology·2026
Same journal

Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial.

The Lancet. Oncology·2026
Same journal

Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.

The Lancet. Oncology·2026
Same journal

Reirradiation for recurrent head and neck squamous cell carcinoma: international expert consensus recommendations endorsed by the Reirradiation Collaborative Group, the European Society for Radiotherapy and Oncology Reirradiation Focus Group, and the American Society for Radiation Oncology.

The Lancet. Oncology·2026
Same journal

European guideline for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma: systematic review and joint statement by the FOSTER consortium, Euro Ewing Consortium, European Society of Paediatric Radiology, and the European Association of Nuclear Medicine.

The Lancet. Oncology·2026
See all related articles

Oncologists can learn valuable lessons from the human immunodeficiency virus (HIV) epidemic, particularly regarding rapid therapeutic advancements and community involvement in research. These insights can improve cancer care and patient outcomes.

Area of Science:

  • Oncology
  • Infectious Diseases
  • Public Health

Background:

  • The human immunodeficiency virus (HIV) epidemic has spurred rapid advancements in medical research and patient care.
  • Political influence and community engagement have significantly shaped the trajectory of HIV research and treatment.

Purpose of the Study:

  • To review the key developments in HIV medicine.
  • To identify transferable lessons for oncologists from the HIV epidemic.
  • To explore how HIV research has influenced drug design and patient care strategies.

Main Methods:

  • Literature review of HIV-related medical developments.
  • Analysis of the impact of political and community factors on HIV research.
  • Discussion of therapeutic targeting, resistance detection, and surrogate endpoints in HIV studies.

Related Experiment Videos

Main Results:

  • Rational drug design has drastically reduced HIV morbidity and mortality.
  • Predictive surrogate endpoints are now crucial for evaluating new treatment protocols.
  • Routine resistance detection enables personalized HIV therapies.
  • Community involvement has proven effective in developing and implementing preventive strategies.

Conclusions:

  • The HIV epidemic offers a model for rapid medical progress and adaptive research strategies.
  • Oncologists can benefit from understanding HIV research methodologies, including personalized medicine and community-based participatory research.
  • Lessons from HIV management can enhance the standard of care in oncology, particularly in areas of drug development and patient advocacy.